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Abstract
Tienilic acid (TA) is a uricosuric diuretic that was withdrawn from the market only months after
its introduction because of reports of serious incidents of drug-induced liver injury including some
fatalities. Its hepatotoxicity is considered to be primarily immunoallergic in nature. Like other
thiophene compounds, TA undergoes biotransformation to a S-oxide metabolite which then reacts
covalently with cellular proteins. To identify protein targets of TA metabolites, we incubated
[14C]-TA with human hepatocytes, separated cellular proteins by 2D gel electrophoresis, and
analyzed proteins in 36 radioactive spots by tryptic digestion followed by LC-MS/MS. Thirty one
spots contained at least one identifiable protein. Sixteen spots contained only one of 14 non-
redundant proteins which were thus considered to be targets of TA metabolites. Six of the 14 were
also found in other radioactive spots that contained from 1 to 3 additional proteins. Eight of the 14
had not been reported to be targets for any reactive metabolite other than TA. The other 15 spots
each contained from 2–4 identifiable proteins, many of which are known targets of other
chemically reactive metabolites, but since adducted peptides were not observed, the identity of the
adducted protein(s) in these spots is ambiguous. Interestingly, all the radioactive spots
corresponded to proteins of low abundance, while many highly abundant proteins in the mixture
showed no radioactivity. Furthermore, of approximately 16 previously reported protein targets of
TA in rat liver (Methogo, R., Dansette, P. and Klarskov, K. (2007) Int. J. Mass Spectrom., 268,
284–295), only one (fumarylacetoacetase) is among the 14 targets identified in this work. One
reason for this difference may be statistical, given that each study identified a small number of
targets from among thousands present in hepatocytes. Another may be the species difference (i.e.
rat vs. human), and still another may be the method of detection of adducted proteins (i.e. Western
blot vs. C-14). Knowledge of human target proteins is very limited. Of more than 350 known
protein targets of reactive metabolites, only 42 are known from human and only 21 of these are
known to be targets for more than one chemical. Nevertheless, the demonstration that human
target proteins can be identified using isolated hepatocytes in vitro should enable the question of
species differences to be addressed more fully in the future.
Introduction
Hepatotoxicity poses a major challenge for the pharmaceutical industry in several ways (1).
It is a significant cause of attrition among candidates in drug development pipelines, where
preclinical testing is effective at weeding out intrinsic hepatotoxins (i.e. compounds that
*Address correspondence to: Dr. Robert P. Hanzlik, University of Kansas, Department of Medicinal Chemistry, Room 4048 Malott
Hall, 1251 Wescoe Hall Drive, Lawrence, KS 66045, Tel. 785-864-3750, Fax 785-864-5326, rhanzlik@ku.edu.
NIH Public Access
Author Manuscript
Chem Res Toxicol. Author manuscript; available in PMC 2013 May 21.
Published in final edited form as:













show reproducible, dose-dependent hepatotoxicity in several species). Drug-induced liver
injury (DILI)1 can also appear unexpectedly after a compound has entered large scale
clinical testing or usage. While infrequent, DILI often leads to the regulatory issuance of
warning labels or even restrictions on usage (e.g., benzbromarone, bosentan, felbamate,
flutamide, nevirapine, ticlopidine, tolcapone, trovafloxacin, valproic acid and zileuton) (2–
4). Such toxicity is often associated with the covalent binding of reactive metabolites to
cellular proteins (5–8).
In other cases, severe drug-induced liver injury may be experienced by a very small number
of individuals among a large population of patients who experience no adverse effects from
the drug. Such idiosyncratic drug-induced liver injury (IDILI) usually leads to withdrawal of
the drug from the market (e.g., benoxaprofen, bromfenac tienilic acid, troglitazone and
zomepirac). Mechanistic understanding of IDILI is limited, but covalent binding of reactive
metabolites to cellular proteins is a common finding, and for several IDILI drugs an
immunological component appears to be involved (3, 9–12).
Tienilic acid (TA, structure 1) is a uricosuric diuretic that was introduced into clinical
practice in the U.S. in 1979, but after only a few months it was withdrawn because of reports
of serious incidents of hepatotoxicity including some fatalities (11, 13). TA is a thiophene
compound, a close isomer of which (TAI, structure 2) shows direct intrinsic hepatotoxicity
in animals (14, 15). TA is a suicide substrate for CYP2C9 (16, 17), but its reactive
metabolites can also bind covalently to other hepatocellular proteins to a small extent (18–
20), which may explain why its toxicity in humans has an immunological component. TAI,
in contrast, does not inactivate CYP2C9, but its metabolites bind extensively to other
microsomal proteins (20). It has even been suggested that the greater incidence of TA
hepatotixicity in the U.S. compared to France might have been due to the presence of a
greater amount of TAI as an impurity in the TA preparation available in the U.S. (15). The
history of TA is long and complicated, but in many ways it still epitomizes the situation
faced by newly marketed drugs. For that reason, and because it presaged IDILI, it is useful
to review it briefly.
The hepatotoxicity of TA observed in open clinical usage was quite unexpected because it
had not shown any propensity to cause liver injury in preclinical safety studies (14).
However, once its association with hepatitis-like liver injury was described in the clinical
literature, subsequent studies with perfused livers from phenobarbital-induced rats (21)
showed that TA (5–50 μM in perfusate) decreased bile flow and BSP clearance to 50% and
20% of control, respectively, while causing a small release of AST (up to 2 times control)
into the perfusate. These findings suggest that at therapeutic concentrations, TA does have
direct effects on the liver and on liver function. More recent investigations (22) showed that
TA is indeed hepatotoxic in rats after glutathione depletion by treatment with buthionine
sulfoximine, a glutamate antimetabolite that inhibits γ-glutamylcysteine synthase. This
observation, together with the fact that glutathione conjugates of TA are formed in vitro and
in vivo (14, 22–24), constitute presumptive evidence for a role of reactive metabolites in the
hepatotoxicity of TA, even if TA does not ordinarily show the frank, acute and dose-
dependent hepatotoxicity often seen with prototypical precursors of reactive metabolites
such as acetaminophen or bromobenzene.
1Abbreviations used: 2DGE, 2-dimensional gel electrophoresis; AST, aspartate aminotransferase; BSP, bromosulfophthalein;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate; CYP2C9, cytochrome P450 2C9; DILI, drug-induced liver
injury; DPPE, dipalmitoyl phosphatidylenthanolamine; DTT, dithiothreitol ((2S,3S)-1,4-bis(sulfanyl)butane-2,3-diol); EDC, 1-
Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride; IDILI, idiosyncratic DILI; HOBt, hydroxybenzotriazole; MM,
molecular mass; PBS, phosphate-buffered isotonic saline (pH 7.4); PE, phosphatidylethanolamine; TA, tienilic acid ([2,3-dichloro-4-
(2-thienylcarbonyl)phenoxy]acetic acid); TAI, tienilic acid isomer ([2,3-dichloro-4-(3-thienylcarbonyl)phenoxy]acetic acid); TPDB,
reactive metabolite target protein database.
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The observation of clinical liver injury due to TA prompted a number of investigations into
the mechanism of its toxicity and that of other thiophene-containing compounds. A specific
focus of many of these studies was on the role of epoxidation vs. S-oxidation of the
thiophene ring; the latter reaction seemed plausible but was not well precedented in organic
chemistry or enzymology (25). Through a combination of drug metabolism and chemical
synthetic studies it was established that thiophene S-oxides were indeed produced
metabolically and that they had considerable reactivity toward nucleophiles, particularly
thiol nucleophiles (23, 25–27). Subsequently, TA metabolites were also demonstrated to
bind covalently to proteins in rat liver (26) and human liver microsomes (28), and to
proteins of yeast transformed to express human cytochrome P450 2C9(2C10) (16) but not
yeast transformed with P450 enzymes from families 1A or 3A (29).
Quite separately, immunological studies of the sera of patients with hepatitis or kidney
disease of various kinds had revealed the presence of auto-antibodies that could react with
either liver or kidney microsomes (anti-LKM). Examination of many anti-LKM samples
eventually lead to the recognition of a subgroup of these sera called anti-LKM2;
surprisingly, these sera came exclusively from patients who were suffering from tienilic
acid-induced hepatitis (13). Eventually, the microsomal antigen for these antisera was
identified as CYP2C9 (30), an enzyme for which TA was later shown to be a moderately
efficient suicide substrate (16, 31).
Other thiophene-containing compounds have also been shown to be suicide substrates for
P450 enzymes, or to form reactive metabolites that covalently bind to proteins, or both. For
example, (±)-suprofen (3), an antiinflammatory agent that is structurally similar to TA, is
also a suicide substrate for CYP2C9 (32, 33). Ticlopidine (4) and clopidogrel (5) are
prodrugs that undergo bioactivation via oxidation at C-5 of the thiophene ring to form a
thiolactone en route to formation of the pharmacologically active ring-opened thiol
carboxylic acid (34–36); similar ring oxidation is also known for TA (28). Zileuton (6) is a
mechanism-based inactivator of CYP1A2. A degradation product of zileuton, 2-
acetylbenzothiophene (2-ABT, 7) (37), undergoes oxidation by P450 3A and 2E enzymes to
an S-oxide that covalently binds to Cys-34 of human serum albumin (38), reacts
spontaneously with NAC and GSH, and inactivates GSTM1-1 and GSTP1-1 in vitro (39). 2-
ABT is also cytotoxic to MCL5 cells that are transformed to express P450 enzymes, but not
to non-transfected control cells (40). The role of drug metabolizing enzymes, particularly
cytochrome P450s, in inducing hepatotoxicity via chemically reactive intermediates is well
established (12). As noted above, the hepatitis caused by tienilic acid is considered to be
immunoallergic in nature, and protein covalent binding is also a prerequisite first step for a
small molecule to elicit an immune response. Thus, even though the net covalent binding of
TA to liver proteins is relatively low (5, 6, 8) compared to some other paradigm
hepatotoxicants such as bromobenzene or acetaminophen (41), it is likely an important step
in TA-induced liver injury.
In view of the growing list of proteins known to be targets for chemically reactive
metabolites of other hepatotoxic chemicals (42), we felt it would be interesting to identify
the target proteins to which TA metabolites bind and to compare them to the targets of other
hepatotoxicants. In this manuscript we report the identification of 14 definite and 29
potential protein targets of tienilic acid in human hepatocytes. This information
complements a recent report by Methogo et al. of the identification of proteins adducted by
tienilic acid metabolites in rat liver in vivo (43).
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Tienilic acid and [14C]-tienilic acid (Amersham GE HealthCare, Piscataway, NJ, 59 Ci/mol,
98% radiochemical purity) were available from a previous study (6). A pool of human
hepatocytes representing a total of six individual donors was created by combining
cryopreserved cell samples obtained from Celcis (Baltimore, MD), InvitroTech (Baltimore,
MD) and CellzDirect (Durham, NC). Williams’ Medium E was obtained from Gibco-
Invitrogen (Grand Island, NY). Trypsin (sequencing grade) was obtained from Roche
(Indianapolis, IN). Sequenal grade urea and CHAPS were obtained from Pierce (Rockford
IL). 4-Vinylpyridine and EDC hydrochloride were obtained from Sigma (St. Louis, MO).
Tris, SDS, glycine, Sequi-blot PVDF membranes (0.2 μm), broad range IEF Standards and
Precision Protein Standards were obtained from Bio-Rad (Hercules, CA). All other
electrophoresis supplies including immobilized pH gradient Dry-Strips and 18.5 × 24.5 cm
SDS-polyacrylamide gels were obtained from GE-HealthCare (Piscataway, NJ). HPLC
grade solvents and analytical grade inorganic salts were obtained from Fisher (St. Louis,
MO). Deionized water (resistivity 18.2 MΩ/cm) was used for preparation of all solutions and
buffers. Dipalmitoyl phosphatidylethanolamine (DPPE) was obtained from Avanti Polar
Lipids Inc. (Alabaster, AL).
Synthesis of the tienilic acid amide conjugate of DPPE (8)
Tienilic acid (5 mg, 15 μmol) and dry dimethylformamide (1 mL) were combined in a small
flask and cooled with an ice bath. EDC hydrochloride (3 mg, 16 μmol), HOBt (2 mg, 15
μmol) and triethylamine (4 μL, 30 μmol) were added in that order, the ice bath was
removed, DPPE (10 mg, 15 μmol) was added, and the reaction was continued overnight at
room temperature. For workup brine was added and the mixture was extracted with ethyl
acetate several times. The extract was back-washed with brine and then sodium bicarbonate
solution and dried over anhydrous sodium sulfate. The crude product was purified by
chromatography over silica gel eluting with MeOH/CHCl3 (20:80 v/v). Yield ca. 4 mg. Rf
~0.3 (MeOH/CHCl3, 20:80 v/v). MS: [M-H]− = 1002.4 (calcd 1002.46).
Hepatocyte incubations
For the incubation of [14C]-TA, the specific activity of the substrate was adjusted to 36.2 Ci/
mol by adding unlabeled TA. The substrate (596 nmol) was pipetted into a 50 mL
Erlenmeyer flask, solvent was removed in vacuo, and a suspension of 9.5 × 106 viable
hepatocytes in 4.0 mL of Williams’ medium E was added to give a final TA concentration of
150 μM. The flask was flushed with O2/CO2 (95:5), sealed with a ground glass stopper, and
incubated with gentle agitation at 37 °C for 2 or 4 h. After incubation the cells were isolated
by centrifugation (500 rpm for 3 min), washed twice with PBS, pelleted and frozen (−80 °C)
until analysis. A second incubation was performed similarly but on a larger scale (i.e. 28.8 ×
106 cells from the same pool in 12 mL medium containing 155 μM unlabeled TA) to
increase the overall yield of adducted protein.
Preparation of Cell Lysates
Human hepatocytes incubated with [14C]-TA were lysed with an isoelectric focusing (IEF)
sample buffer (IPG strip rehydration solution, RHS) containing 9 M urea, 4% CHAPS, a
mixture of ampholites (IPG buffer, pH 3-10NL), 65 mM DTT and a trace of bromophenol
blue. Briefly, to the cell pellet obtained from the incubation with [14C]-TA (65 mg wet
weight) was added 450 μL of RHS, the mixture was then gently mixed by vortex, then kept
overnight at room temperature to complete solubilisation. Insoluble materials were then
removed by centrifugation (15000g, 15 min), and the resulting clear supernatant aliquotted.
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An aliquot containing 6 × 105 dpm 14C was further diluted with RHS (1:2, v/v) and
immediately infused into an IPG strip. After isoelectric focusing, development in the second
dimension, and transblotting, the blot was subjected to phosphorimaging as described below.
In addition, small aliquots (1500–2000 dpm) were submitted to one-dimensional SDS-
PAGE, followed by phosphorimaging.
The cell pellet from the incubation of hepatocytes with unlabeled TA (193 mg wet weight)
was resuspended by pipetting with 1 ml of KPBS (25 mM potassium phosphate, 150 mM
sodium chloride, pH 7.4), to give a total volume of 1.2 mL. An aliquot of this suspension
(ca. 15%) was reserved for lipid analysis (see below) and the remainder was centrifuged
(100g × 5 min). The resulting pellet (ca. 162 mg wet weight) was mixed with 1215 μL of
RHS and solubilized exactly as the 14C-containing sample, above. The resulting clear
solubilisate was split into 6 equal aliquots, each corresponding to ca. 2 × 106 incubated cells.
One of the aliquots was reserved for 1D gel electrophoresis and the remaining five aliquots
were immediately submitted to 2DGE separation followed by proteomics analysis as
described below.
Preparation of lipid extracts and MS/MS analysis of phospholipids
A phospholipid fraction from the incubated cells was obtained by Folch extraction and the
extract was analyzed by MS/MS as described earlier (44). A synthetic preparation of the
tienilic acid amide conjugate of DPPE was used as a standard.
Electrophoresis, phosphorimaging and in-gel digestion
These standard procedures were carried out essentially as described earlier (45–47).
Mass-spectrometry of tryptic digests and protein identification
Digested protein samples were submitted to a capillary LC-MS/MS using a LTQ-FT hybrid
linear quadrupole ion trap Fourier transform ion cyclotron resonance (FT-ICR) mass
spectrometer (ThermoFinnigan, Bremen, Germany) as described (48). Raw data files were
processed using BioWorks 3.2 software followed by peptide/protein identification using
Sequest (ThermoFinnigan), Mascot (Matrix Science, version 2.2) and X!Tandem
(www.thegpm.org) database-searching programs with SwissProt 2011 database with a
fragment ion mass tolerance of 0.20 Da and a parent ion tolerance of 20 ppm. The S-
pyridylethyl (+105) derivative of cysteine residues and methionine S-oxidation (+16) were
specified as variable modifications. Possible mass shifts for putative adducts of TA to lysine
(+312), as well as to cysteine (+328, +346) were also considered (Scheme 2). The lysine
adduct could conceivably form via activation of the carboxyl group of TA as either an acyl
glucuronide or an acyl coenzyme A thioester. Alternatively, either epoxidation or S-
oxidation of the thiophene ring could activate the molecule toward protein sulfhydryl groups
to give a +346 adduct, and dehydration of either of these adducts would lead to a +328
adduct.
Scaffold software (Proteome Software Inc., version 3.3.1) was used to combine and validate
MS/MS based peptide and protein identifications. Peptide identifications with greater than
50% probability as specified by the Peptide Prophet algorithm (49) were accepted for
reporting protein coverage. Taking into account the high accuracy of peptide mass
determination by LTQ-FTMS (usually within 10 ppm), we performed, for select samples, an
additional search of SwissProt database using parent peptide-ion masses (using Decon
software; http://omics.pnl.gov/software/DeconTools) and MS-Fit
(http://prospector.ucsf.edu) or Mascot searching software. For several identified proteins, we
performed visual examination of raw MS and MS/MS spectra for the presence of ion-
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clusters showing chlorine natural abundance isotopic signature and, independently, for the
presence of peptide-ions with calculated mass shifts for putative TA-adducts (see above).
Results and Discussion
After incubation of hepatocytes with [14C]-TA the cells were harvested by centrifugation,
dissolved in lysis buffer and re-centrifuged. The soluble supernatant (470 μL) contained
1.06 μCi of radioactivity, corresponding to 0.453 nmol-equiv. of TA per mg cell wet weight,
while the insoluble material contained less than 4% of total 14C. SDS-PAGE analysis of the
solubilizate showed numerous bands of protein with a majority of the density in the region
of 25–75 kDa (Figure 1, left). Phosphorimaging of a blot of this gel showed a prominent
band of radioactivity that increased with incubation time around 50–60 kDa, along with
smaller amounts of radioactivity at lower molecular mass. A similar 1D electrophoresis/
phosphorimaging result was reported by Bonierbale et al. (20), who incubated [14C]-TA
with human liver microsomes. Their protein band reacted with anti-TA-protein adduct
antibodies and with anti-LKM2 antibodies, and was therefore presumed to represent
CYP2C9. The appearance of a band of radioactivity around 50–60 kDa in both studies is
consistent with the fact that TA is an efficient suicide substrate for CYP2C9 and labels that
protein with essentially 1:1 stoichiometry (16, 19). This result from 1-dimensional SDS/
PAGE is significant because many membrane proteins, including P450 enzymes, do not
behave well under conditions of 2D gel electrophoresis and are generally not observable in
this way (50).
The remainder of the 14C cell extract was submitted to 2D gel electrophoresis in parallel
with the corresponding soluble fraction from cells incubated with non-radioactive TA. A
representative blot image is shown in Figure 2. Thirty six of the spots contained
radioactivity that was low but detectable by phosphorimaging (data not shown).
Interestingly, essentially all of the radioactive protein spots were associated with low-
abundance proteins, while numerous spots for abundant proteins contained no detectable
radioactivity (see below).
In addition to the numerous small protein spots distributed across the gel, a large diffuse
non-protein staining spot containing a considerable amount of radioactivity appeared near
the low pI/low MW corner of the blot. We observed a similar phenomenon previously in the
2DGE of microsomal proteins from the livers of rats treated with [14C]-bromobenzene (46)
or [14C]-thiobenzamide (48). Because this material came from the microsomal fraction but
did not stain as protein and was not observed in the corresponding cytosol fractions, we
suspected that it might be lipid-derived. In previous work we demonstrated that S-oxidative
bioactivation of thiobenzamide in rat liver in vivo leads to extensive acylation of the amine
group in phosphatidylethanolamine (PE) lipids (44). Conceivably, a TA-amide adduct of PE
lipids such as structure 8 could account for this radioactive non-protein material. Such an
adduct could potentially be formed via a reactive acyl glucuronide or acyl coenzyme A
thioester conjugate of TA, although we know of no specific precedent for such a process. To
test this hypothesis we prepared a synthetic standard of the TA amide of dipalmitoyl
phosphatidylethanolamine (TA-DPPE, 8), characterized its behavior in MS and MS/MS, and
used this information to search for analogous TA-PE amides in Folch extracts of the low pI/
low MW area of the actual 2D gels from the TA-hepatocyte incubations.
TA-DPPE is readily detectable by electrospray ionization in both positive and negative ion
modes, the molar response for MH+ being 2.4 times that of M-H−, but when spiked into
Folch extract of liver lipids at a mass ratio of 7% that of total lipids, the M-H− ion gives a
20-fold better s/n ratio due to the high background of other lipids detected above 900 u in
positive mode. To detect TA-modified PE lipids in the lipid pool extracted from hepatocytes
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incubated with TA, we first explored head group-specific tandem MS scans using synthetic
TA-DPPE. In negative ion mode, the most abundant head group specific product ions from
M-H− were m/z 271 (structure 9) and m/z 452 (structure 10). In positive ion mode, the most
abundant head group-specific product ion from MH+ is m/z 551 representing a neutral loss
of 453 (i.e. 10+H+), in analogy to the “classic” characteristic neutral loss of 141 from
unmodified PEs. The neutral loss of 453 in positive ion mode detects the molecular ion of
TA-DPPE with 330 times the sensitivity of detection by precursors m/z 270.9 in negative
ion mode. When TA-DPPE is spiked into Folch extract of control liver tissue to the extent of
7% of total lipids, the scan for neutral loss of 453 detects the TA-DPPE with a s/n ratio of
better than 180, which gives a detection limit of 0.04% of total lipid. Nevertheless, we
observed no lipids, modified or unmodified, in the Folch extracts from the 2D gels. In
corresponding Folch extracts from whole hepatocytes incubated with TA we observed all
the usual major classes of phospholipids but no acylated PE lipids were detected. Thus for
all practical purposes, TA-PE lipid adducts are not formed when hepatocytes are incubated
with TA. This is very different from the situation with thiobenzamide, which modifies (i.e.
acylates) up to 23% of total microsomal PE lipids in rat liver (44). The nature of the
radioactive material in the low MM/low pI area of the gel thus remains to be determined.
Protein spots corresponding to radioactive spots on the phosphorimaged blot were excised
from the five non-radioactive gels, pooled, digested with trypsin, and the digests were
analyzed by LC-MS/MS. Thirty-one of the spots contained at least one identifiable protein,
and 43 proteins were identified overall (Table 1). Automated searching did not reveal the
presence of TA-adducted peptides such as those indicated in Scheme 2 in any of the protein
digests examined. This was not surprising in vew of the small amount of sample we had to
work with and the generally low level of overall protein adduction. Therefore, we also
performed thorough visual examination of mass spectra for the presence of ion clusters with
a chlorine isotopic signature, and for the presence of peptide ions with calculated mass shifts
corresponding to putative TA-derived adducts, but neither approach resulted in detection of
any adducts.
Sixteen of the 31 protein spots analyzed (Group A) contained only a single detectable
protein, hence the proteins in these radioactive spots are taken to be target proteins for TA
metabolites. However, three of these 16 spots each contained the same single protein, so the
total number of non-redundant target proteins identified is 14. Rat or mouse orthologs of six
of these 14 human proteins are already known as targets for reactive metabolites of four
different chemicals, whereas eight of the target proteins in Group A are identified here for
the first time.
The other 15 spots each contained from two to four identifiable proteins (Groups B and C).
Since we did not observe any adducted peptides in the digests of these samples, the identity
of the target protein(s) in these spots is necessarily ambiguous. Interestingly, however,
Group B of Table 1 indicates that six of the 15 multi-protein spots (i.e. spots # 1, 10, 12, 13,
22 and 34.1) each contained one target protein from Group A, while one spot (# 27)
contained two target proteins from Group A. When analyzing cellular proteins by 2DGE it is
not uncommon to observe the same protein appearing in several spots of the same MW but
different pI (45, 46, 51, 52). Thus it is possible, perhaps likely, that the radioactivity
observed in these seven multi-protein spots is associated with the same target proteins that
were also observed in single protein spots (Group A), but since we cannot rule out the
possibility that other proteins in these spots may also be adducted, they are not excluded
from Table 1. Altogether the 15 multi-protein spots in Table 1 contain 29 non-redundant
proteins (Group C) whose target status is ambiguous. As indicated in Table 1, however, the
Reactive Metabolite Target Protein Database (TPDB)
(http://tpdb.medchem.ku.edu:8080/protein_database/) indicates that rat or mouse orthologs
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of 14 of these 29 human proteins are already known as targets for one or more of 12
different chemicals.
Because many membrane proteins do not behave well on 2D gel electrophoresis, we also
performed mass spectral analysis of peptides produced by tryptic digestion of proteins in 18
bands cut from a 1D gel separation of the same solubilized proteins used for our 2D gel
analysis. Using the same protein identification protocols we identified more than 400
proteins, with the most populated region being in the 45–60 kDa range as expected (Figure
1). Among the identified proteins we observed cytochromes P450 2C9, 3A4, 2A6 and 2E1
with sequence coverages from 7–38%. No peptides with calculated mass shifts for putative
adducts were detected. Possible reasons for this include the low level of adduction, low
sequence coverage, and possible instability of adducts in the mass spectrometer. More than
100 proteins were identified with sequence coverages in excess of 70%, but even among
these no adducts were observed. Interestingly, no adducted peptides from CYP2C9 were
observed by Koenigs et al. even when purified and reconstituted 2C9 was incubated with
tienilic acid in vitro, although in this case whole molecule mass spectrometry clearly showed
adduction of the 2C9 protein by tienilic acid (17).
Among the 14 TA target proteins listed in Group A of Table 1, eight are involved in fatty
acid uptake or metabolism. The mitochondrial enzymes short-chain specific acyl-CoA
dehydrogenase, medium-chain specific acyl-CoA dehydrogenase, isovaleryl-CoA
dehydrogenase and 2-oxoisovalerate dehydrogenase subunit alpha, and the cytosolic enzyme
fumarylacetoacetase, all play key roles in metabolism of fatty acids or branched chain keto
acids derived from amino acid metabolism, and all are associated with genetically inherited
deficiency diseases that have severe consequences at the cellular and organismal level.
Another mitochondrial enzyme targeted by TA, enoyl-CoA hydratase, has been implicated
in non-alcoholic fatty liver disease, and siRNA knockdown of this enzyme leads to
increased accumulation of lipid droplets in both a cell line and in vivo (53). Liver fatty acid
binding protein (LFABP), a major target protein for metabolites of bromobenzene (45) and
thiobenzamide (48), has been suggested to be an early marker for kidney disease and acute
kidney failure (54), and transgenic mice expressing human LFABP show moderate
protection against kidney disease in several models of nephropathy (55, 56).
Three of the Group A proteins are very well known and of special interest from the point of
view of their potential role in cytotoxicity, namely, nucleophosmin (NPM), prohibitin (PHB)
and Raf kinase inhibitory protein (RKIP, also known as phosphatidylethanolamine binding
protein or PEBP-1). Nucleophosmin is a ubiquitously expressed phosphoprotein that moves
between the cytoplasm, nucleus and nucleolus and is associated with lipid rafts (reviews:
(57, 58)). It binds to DNA, RNA, histones, unfolded proteins and NF-kappaB, and is
involved in a multitude of cellular processes including protein chaperoning, cell
proliferation, chromatin assembly and disassembly, transcription co-activation, stress
response and apoptosis. It forms a dimer of pentamers having a ring-like structure that is no
doubt related to its chaperone function. Multiple post-translational modifications of NPM
are known, including acetylation, phosphorylation (≥ 6 sites), SUMOylation, ubiquitination,
and poly-(ADP-ribosyl)-ation, and are variously associated with specific functions and/or
subcellular localizations of NPM. Cellular levels of NPM increase three-fold upon exposure
of human lung epithelial cells to chlorobenzene and 1,2-dichlorobenzene (both of which are
significantly hepatotoxic as well as pneumotoxic) (59). NPM is one of several proteins that
become glutathionylated in 3T3 cells upon treatment with a nitric-oxide releasing prodrug,
and this covalent modification was linked to the activation of kinases associated with stress
response and cell death pathways including p38, JNK and c-jun (60). Interestingly, NPM (−/
−) null mice are embryonically non-viable.
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RKIP and its orthologs constitute a large family of proteins conserved throughout evolution
and widely expressed in eukaryotic organisms (reviews: (61–63)). It is a PE binding protein
having a discrete ligand binding site that binds cacodylate and could accommodate the head
group of a phospholipid. Depending on its phosphorylation state it can inhibit MAP kinases
(Raf-MEK-ERK), G-protein coupled receptor kinases and NF-kappaB kinases. In doing so it
integrates cross-talk in pathways initiated by diverse environmental stimuli that affect
cellular proliferation, differentiation, survival, angiogenesis, metastasis, apoptosis and
resistance to apoptosis. In the male mouse, deletion of the RKIP gene leads to decreased
rates of reproductive success with wild type females, but knockout females have normal
rates of reproductive success with wild type males. Because of its central position
overlapping with several major signaling cascades, there is much interest in RKIP as a
potential therapeutic target (63), and one inhibitor (locostatin, (4S)-3-[(E)-but-2-enoyl]-4-
benzyl-2-oxazolidinone) is commercially available.
Members of the prohibitin family of proteins are highly conserved evolutionarily (reviews:
(64–66)). They are subdivided into two groups, PBH1 and PHB2, and at least one from each
group is found in every known eukaryotic genome, suggesting that the two types are not
functionally redundant. They function in both the cytosol and mitochondria and are required
for embryonic development in C. elegans, mice and plants. Rat, mouse and human PHBs are
nearly identical but they are known to undergo a wide range of post-translational
modifications. For example they are phosphorylated by insulin-, IGF-1- and EGF-receptor
tyrosine kinases. PHBs localize to the cell membrane and inner mitochondrial membrane as
well as to the cytoplasm and nucleus depending on cell type and status. PHB1 and PHB2
function together as a 1 MDa complex of 12–16 1:1 heterodimers associated into a ring-like
structure anchored to the membrane by transmembrane helices. The complex is speculated
to be a hydrolase/unfoldase chaperone that protects mitochondrial membranes from
unfolded or improperly associated proteins. PHBs are also thought to act as protein scaffolds
to facilitate cross-talk among signaling cascades, they are essential in metabolism, cell
proliferation and immune regulation, and they play important roles in PI3K/Akt, Raf/ERK
and TGF-beta signaling pathways. Knockdown of PHB expression is deleterious in a variety
of cell types and gene deletion is embryonically lethal in mice and flies, whereas
overexpression protects cardiomyocytes from hypoxia. Given the pleiotropic roles of PHB,
RKIP and NMP in overall cell function, and the multiplicity of post-translational
modifications involved in modulating these roles, it would not be surprising that their post-
translational modification by chemically reactive xenobiotic metabolites could contribute to
cell injury or death.
In an earlier study Methogo et al. (43) identified 15 proteins likely to be modified by
reactive metabolites of TA in rat liver. However, four of these proteins including PDI-A1,
adenosylhomocysteinase, arginase and hsc 73, were only observed in multi-protein spots, so
their adduction by TA is ambiguous. According to the TPDB, hsc 73 is a known target for
butylated hydroxy toluene and naphthalene, arginase is a known target for bromobenzene
and thiobenzamide, adenosylhomocysteinase is not listed as a target, and PDI-A1 is a target
for ten other chemicals. On the other hand, five proteins identified by Methogo et al. as
appearing in single-protein spots were not listed in their summary list of likely targets. These
proteins (and other chemicals known to target them) include albumin (bromobenzene and
thiobenzamide), beta actin (butylated hydroxytoluene and mycophenolic acid), 4-
hydroxyphenylpuruvate dioxygenase (mycophenolic acid), and UDP-glucose
pyrophosphorylase and keratin Kb1. Amongst all of the above rat liver proteins only two,
fumarylacetoacetase and triosephosphate isomerase, are in common with the human
hepatocyte target proteins listed in Table 1. There could be several reasons for the
differences between the two lists of TA targets. One could be methodological, in that
Methogo used western blotting with anti-adduct antibodies to detect adducted proteins,
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whereas we used radioactivity and phosphorimaging. Another is that species differences
between rat and human may be larger than expected. A third potential reason is purely
statistical, i.e., given the very large number of potential target proteins vs. the small size of
each target protein list, it is not surprising that the overlap between the two lists from two
different labs might be small.
Currently the TPDB contains information on 540 individual adduction events involving 46
different chemicals and 356 non-redundant proteins, but only 42 of these proteins are human
proteins, only 21 of these 42 are targets for more than one chemical, and only 11 of these 21
have rat or mouse orthologs that are also known to be targets for reactive metabolites.
Viewed another way, the 42 human proteins in the TPDB include albumin, hemoglobin, 8
isoforms of tubulin that were adducted relatively selectively by exposing A549 lung cancer
cells to chemically reactive isothiocyanates that may not require metabolic activation, and 8
members of the serine hydrolase family that are adducted very selectively by nerve gas
analogs. While the numbers of target proteins known for several “paradigm” protoxins are
relatively good (e.g., 62 for thiobenzamide, 46 for teucrin, 45 for bromobenzene, 40 for
naphthalene, 34 for butylated hydroxytoluene, and 33 for acetaminophen), the data on
protein targets of the other 40 chemicals in the TPDB are much more sparse, and the overall
data for human proteins are particularly sparse. It is thus difficult to draw mechanistic
conclusions, or even to formulate specific hypotheses, from comparisons of small sets of
targets for a few chemical agents. It is a stark realization that the 356 known proteins in the
TPDB represent not an abundance but rather a paucity of information within the vast space
defined by the dimensions of chemical agent, animal species, target tissue and individual
protein. This in turn raises an important question about the degree of concordance between
human targets vs. animal targets across the other variables (i.e. chemical agent and tissue).
Unfortunately, this question can not be answered with currently available data, but given the
demonstrated feasibility of identifing reactive metabolite target proteins from isolated
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SDS-PAGE gel (left) and phosphorimaging analysis (right) of cellular proteins from human
hepatocytes incubated with [14C]-tienilic acid for 2 or 4 h. S = marker protein standards.
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Image of Coomassie stained 2D gel analysis of cellular proteins from human hepatocytes
incubated with [14C]-tienilic acid for 2 h. The pH range is from ca. 4 at the far left to 10.0 at
the right (but excluding the numbered molecular mass standards at the far right). Proteins
found in the numbered spots are listed in Table 1, and all spots other than 40 and 41 were
radioactive. Note that some of the spots were faint and do not reproduce well in the
photograph, but they are clearly visible to an experienced operator, and the mass
spectrometer clearly identified protein(s) in their tryptic digests.
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Structures of tienilic acid (1), its isomer (2), and other thiophene compounds.
Koen et al. Page 17














Structures of potential peptide adducts of reactive TA metabolites.
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Structure and mass spectral fragmentation of model TA-phospholipid adduct.
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